Featured Publications
Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
Sehested T, Bjerre J, Ku S, Chang A, Jahansouz A, Owens D, Hlatky M, Goldhaber-Fiebert J. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiology 2019, 4: 128-135. PMID: 30649147, PMCID: PMC6439626, DOI: 10.1001/jamacardio.2018.4566.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioIncremental cost-effectiveness ratioRecurrent cardiovascular eventsHealth-related quality of lifeStandard of careCanakinumab Anti-inflammatory Thrombosis Outcomes StudyHs-CRP levelsLung cancer incidenceHealth-related qualityMyocardial infarctionCardiovascular eventsRate of recurrent MIHealth care sector perspectiveReduced all-cause mortalityQuality of lifeAll-cause mortalityCost-effectiveUS health care sector perspectiveHs-CRPCancer incidenceRisk of recurrent cardiovascular eventsMain OutcomesHigh-sensitivity C-reactive proteinSubstantial price reductions
2014
Evaluating the Cost-effectiveness of Catheter Ablation of Atrial Fibrillation.
Chang A, Kaiser D, Ullal A, Perino A, Heidenreich P, Turakhia M. Evaluating the Cost-effectiveness of Catheter Ablation of Atrial Fibrillation. Arrhythmia & Electrophysiology Review 2014, 3: 177-83. PMID: 26835088, PMCID: PMC4711535, DOI: 10.15420/aer.2014.3.3.177.Peer-Reviewed Original ResearchAtrial fibrillationCatheter ablation of atrial fibrillationConventional antiarrhythmic drug therapyAblation of atrial fibrillationAssociated with considerable morbidityQuality of lifeCost-effectiveness analysisAntiarrhythmic drug therapyFirst-line therapyAF ablationPulmonary veinsCatheter ablationSinus rhythmDrug therapyCardiology settingCardiac conditionsProcedural costsCost-effectiveSurrounding tissuesTherapyHealthcare utilisationPrimary careAblationFibrillation